Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time-of-day immune checkpoint inhibitor treatment in advanced gastric cancer
jRCTs041260120Phase 3Recruiting
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms). Primary endpoint: Overall survival. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs041260120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260120.